A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cellsChristopher A. Vakulskas, Mark A. Behlke|Nature Medicine|2018Cited by 796
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic DiseaseKiran Musunuru, Rebecca C. Ahrens‐Nicklas, Julia Hacker et al.|New England Journal of Medicine|2025Cited by 272
AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicinesLiyang Zhang, Christopher A. Vakulskas|Nature Communications|2021Cited by 171